Wells Fargo initiated coverage on AnaptysBio with a new price target
$ANAB
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of AnaptysBio with a rating of Overweight and set a new price target of $56.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | $38.00 | Neutral → Buy | H.C. Wainwright |
| 2/4/2025 | $25.00 | Outperform | Wolfe Research |
| 12/11/2024 | $52.00 → $19.00 | Buy → Neutral | H.C. Wainwright |
| 12/2/2024 | Buy → Neutral | BTIG Research | |
| 7/22/2024 | $55.00 | Buy | H.C. Wainwright |
| 7/19/2024 | $29.00 → $69.00 | Neutral → Overweight | JP Morgan |
| 4/16/2024 | $47.00 | Outperform | Leerink Partners |
| 4/11/2024 | $56.00 | Overweight | Wells Fargo |
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00
Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared to standard of care biologics or JAKsMax response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50Durable responses for at least two months off drug, with potential for extended dosing intervals (e.g. Q8W) in the maintenance settingConference call and webcast today at 4:15pm ET/1:15pm PT SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management will be joined by Paul Emery, M.D., professor, Rheumatology, University of Leeds, Leeds Biomedical Research Centre, U.K. and Jonathan Graf, M.D., professor of Medicine, Rheumatology, U
Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)